Choice of modelling technique for evaluating health care interventions

Economic evaluation, such as cost effectiveness analysis, provides a method for comparing healthcare interventions. These evaluations often use modelling techniques such as decision trees, Markov processes and discrete event simulations (DES). With the aid of examples from coronary heart disease, the use of these techniques in different health care situations is discussed. Guidelines for the choice of modelling technique are developed according to the characteristics of the health care intervention.The choice of modelling technique is shown to depend on the acceptance of the modelling technique, model ‘error’, model appropriateness, dimensionality and ease and speed of model development. Generally decision trees are suitable for acute interventions but they cannot model recursion and Markov models are suitable for simple chronic interventions. It is further recommended that population based models be used in order to provide health care outcomes for the likely cost, health benefits and cost effectiveness of the intervention. The population approach will complicate the construction of the model. DES will allow the modeller to construct more complex, dynamic and accurate systems but these may involve a corresponding increase in development time and expense. The modeller will need to make a judgement on the necessary complexity of the model in terms of interaction of individuals and model size and whether queuing for resources, resource constraints or the interactions between individuals are significant issues in the health care system.

[1]  Peter H. Millard,et al.  A continuous time Markov model for the length of stay of elderly people in institutional long‐term care , 2005 .

[2]  G. Bevan,et al.  "Systematic" , 1966, Comput. J..

[3]  R Davies,et al.  Modelling patient flows and resource provision in health systems , 1994 .

[4]  C. Bell,et al.  The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.

[5]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  T. Jefferson,et al.  Is vaccination against hepatitis B efficient? A review of world literature. , 1994, Health economics.

[7]  I. U. Haq,et al.  Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment , 1999, Heart.

[8]  Bhash Naidoo,et al.  The Development of a Simulation Model of Primary Prevention Strategies for Coronary Heart Disease , 2002, Health care management science.

[9]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  P Tappenden,et al.  Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. , 2004, Health technology assessment.

[11]  F A Sonnenberg,et al.  Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.

[12]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[13]  D. Owens,et al.  Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. , 2003, The American journal of medicine.

[14]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[15]  K Cooper,et al.  Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction , 2005, Emergency Medicine Journal.

[16]  R. G. Evans Manufacturing Consensus, Marketing Truth: Guidelines for Economic Evaluation , 1995, Annals of Internal Medicine.

[17]  Ruth Davies,et al.  Using simulation modelling for evaluating screening services for diabetic retinopathy , 2000, J. Oper. Res. Soc..

[18]  M C Weinstein,et al.  Methodologic issues in policy modeling for cardiovascular disease. , 1989, Journal of the American College of Cardiology.

[19]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[20]  Ruth Davies,et al.  Simulating health systems: modelling problems and software solutions , 1995 .

[21]  Ruth Davies,et al.  The Development of a Simulation Model of the Treatment of Coronary Heart Disease , 2002, Health care management science.

[22]  M. Gold,et al.  Panel on cost-effectiveness in health and medicine. , 1996, Medical care.

[23]  Sheldon Howard Jacobson,et al.  Application of discrete-event simulation in health care clinics: A survey , 1999, J. Oper. Res. Soc..

[24]  M. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[25]  C. Lyles,et al.  The view from managed care pharmacy. , 1996, Health affairs.

[26]  M C Weinstein,et al.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[27]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[28]  Manouche Tavakoli,et al.  Use of Quality Adjusted Life Years and Life Years Gained as Benchmarks in Economic Evaluations: A Critical Appraisal , 2004, Health care management science.

[29]  R. Steingart,et al.  Non-Q wave myocardial infarction: Identification of high and low risk subsets by clinical variables☆ , 1989 .

[30]  N Melão,et al.  Use of business process simulation: A survey of practitioners , 2003, J. Oper. Res. Soc..

[31]  D. Zinner,et al.  Are Methods for Estimating QALYs in Cost-Effectiveness Analyses Improving? , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[32]  Ruth Davies,et al.  The evaluation of disease prevention and treatment using simulation models , 2003, Eur. J. Oper. Res..

[33]  B R Luce,et al.  Health and economic outcomes modeling practices: a suggested framework. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[35]  Stirling Bryan,et al.  Modelling in the economic evaluation of health care: selecting the appropriate approach , 2004, Journal of health services research & policy.

[36]  W. R. Taylor,et al.  Health Care CBA/CEA: An Update on the Growth and Composition of the Literature , 1993, Medical care.

[37]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[38]  A Briggs,et al.  Sensitivity analysis in economic evaluation: a review of published studies. , 1995, Health economics.

[39]  Thomas C. Chalmers,et al.  Economic Analysis in Randomized Control Trials , 1992, Medical care.

[40]  A. Elixhauser,et al.  Health care CBA and CEA from 1991 to 1996: an updated bibliography. , 1998, Medical care.

[41]  J Karnon,et al.  Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.

[42]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[43]  Jonathan Karnon,et al.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.

[44]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[45]  L. Goldman,et al.  Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. , 1987, American journal of public health.

[46]  M C Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[47]  Stewart Robinson,et al.  Simulation: The Practice of Model Development and Use , 2004 .

[48]  J. Mauskopf,et al.  Prevalence-based economic evaluation. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[49]  J. Seymour,et al.  A TOOL TO IMPROVE QUALITY OF REPORTING PUBLISHED ECONOMIC ANALYSES , 2000, International Journal of Technology Assessment in Health Care.

[50]  Lyn C. Thomas,et al.  A portfolio of purchase contracts—an example of solving large-scale dynamic programming on parallel computers , 1995 .

[51]  K Cooper,et al.  A review of health care models for coronary heart disease interventions , 2006, Health care management science.

[52]  T. Jefferson,et al.  Quality of systematic reviews of economic evaluations in health care. , 2002, JAMA.